First in Human Safety of [68Ga]-NOTA-hGZP- PET Imaging in Subjects Receiving Checkpoint Inhibitor Immunotherapy
Latest Information Update: 22 Feb 2024
At a glance
- Drugs Gallium-68 NOTA hGZP (Primary)
- Indications Cancer; Malignant melanoma; Non-small cell lung cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Cytosite Bio
Most Recent Events
- 28 Nov 2022 According to a Cytosite Bio media release, results from this trial were presented at the Radiological Society of North American (RSNA) Annual Meeting 2022.
- 28 Nov 2022 Results (n=8) published in the Cytosite Bio Media Release.
- 01 Jun 2022 Planned number of patients changed from 20 to 30.